Announcement








                  Company Celltech Group PLC
                  TIDMCCH
                  Headline Further re Offer for OGS
                  Released 15:03 26 Mar 2003
                  Number 2361J






NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA
OR JAPAN

26 March 2003
CELLTECH GROUP PLC ("CELLTECH")
CASH OFFER FOR OXFORD GLYCOSCIENCES PLC ("OGS")

Celltech notes the announcements released this morning by both OGS and CAT.
Since the announcement on Wednesday, 26 February 2003 of Celltech's all
cash offer for OGS, OGS has repeatedly suggested to its shareholders that
potential further offers for OGS (including a possible revised offer from
CAT) may be forthcoming.
As OGS Shareholders will be aware, none of these potential offers for OGS
have yet materialised and there is no guarantee that any such offer for OGS
will be forthcoming. Celltech's all cash offer of 182 pence per OGS Share
represents an increasingly generous offer for OGS as, due to OGS' continuing
cash burn, the value of OGS and its assets to Celltech, or any other
potential offeror, declines as time progresses.
OGS Shareholders should be aware that based on the mid price of a CAT Share
at 12 noon today, the implied value of OGS under the all paper CAT merger
offer, is GBP 66.1 million or 118.5 pence per OGS share. In comparison, the
value of Celltech's all cash offer is GBP 101.4 million or 182 pence per OGS
Share representing an additional 63.5 pence over the implied value of an
OGS Share under the CAT merger offer.
Celltech wishes to remind OGS shareholders that the first closing date is
Monday, 31 March 2003 and encourages OGS Shareholders to accept its all
cash offer.
Enquiries:
For further information contact:
      Celltech Group plc
      Telephone: +44 (0)1753 534 655
      Dr Peter Fellner, Chief Executive
      Peter Allen, Chief Financial Officer
      Richard Bungay, Director of Corporate Communications

      JPMorganTelephone:
      +44 (0)20 7742 4000
      Bernard Taylor, Vice Chairman
      Julian Oakley, Managing Director
      Brunswick London Telephone: +44 (0)20 7404 5959
      Jon Coles
      Fiona Fong
      Brunswick New York Telephone: +1 212 333 3810
      Cindy Leggett-Flynn


Terms defined in the Offer Document have the same meaning when used in
this announcement.
Celltech and JPMorgan, acting on its behalf outside the United States,
are offering to purchase all of the issued and to be issued ordinary
shares of 5 pence each in OGS (including those represented by OGS ADSs)
at a price of 182 pence per OGS Share.
This announcement does not constitute an offer or invitation to purchase
any securities or a solicitation of an offer to buy any securities,
pursuant to the Offer or otherwise. The Offer is being made solely by
the Offer Document and the Acceptance Forms accompanying the Offer
Document, which contain the full terms and conditions of the Offer,
including details of how the Offer may be accepted. Celltech filed
with the SEC a Tender Offer Statement on Schedule TO containing the
Offer Document and other related information on 3 March 2003. Free
copies of those documents are available on the SEC's website at
www.sec.gov. The Offer Document and the Acceptance Forms accompanying
the Offer ocument have been made available to all OGS Securityholders
at no charge to them. OGS Securityholders are advised to read the Offer
Document and the accompanying Acceptance Forms which have been sent to
them because they contain important information. OGS Securityholders in
the United States are also advised to read the Tender Offer Statement
because it contains important information. Unless otherwise determined
by Celltech and permitted by applicable law and regulation, the Offer
(including the Loan Note Alternative) is not being made, directly or
indirectly, in or into, or by use of the mails of, or by any other
means or instrumentality (including, without limitation, telephonically
or electronically) of interstate or foreign commerce of, or of any
facility of a national securities exchange of Canada, nor is it being
made in or into Australia or Japan and the Offer is not capable of
acceptance by any uch use, means, instrumentality or facilities or
from within Australia, Canada or Japan. Accordingly, unless otherwise
determined by Celltech and permitted by applicable law and regulation,
neither copies of this announcement nor any other documents relating to
the Offer have been, or may be, mailed or otherwise forwarded,
distributed or sent in or into Australia, Canada or Japan and persons
receiving such documents (including custodians, nominees and trustees)
must not istribute or send them in, into or from such jurisdictions.
The Loan Notes to be issued pursuant to the Loan Note Alternative
available under the Offer have not been, and will not be, listed on any
stock exchange and have not been and will not be registered under the
US Securities Act of 1933, as amended or under any relevant securities
laws of any state or other jurisdiction of the United States, or under
the relevant securities laws of Australia, Canada or Japan or any other
jurisdiction. Accordingly, unless an exemption under such relevant laws
is available, Loan Notes may not be offered, sold, re-sold or delivered,
directly or indirectly, in, into or from the United States, Australia,
Canada or Japan or any other jurisdiction in which an offer of Loan Notes
would constitute a violation of relevant laws or require registration of
the Loan Notes, or to or for the account or benefit of any US Person or
resident of Australia, Canada or Japan or any other such jurisdiction.

THE OFFER WILL REMAIN OPEN FOR ACCEPTANCE DURING THE INITIAL OFFER PERIOD.
THE INITIAL OFFER PERIOD FOR ACCEPTANCES AND WITHDRAWALS WILL EXPIRE AT
3:00 P.M. (LONDON TIME), 10:00 A.M. (NEW YORK CITY TIME), ON 31 MARCH
2003, UNLESS EXTENDED TO A LATER CLOSING DATE. AT THE CONCLUSION OF THE
INITIAL OFFER PERIOD, IF ALL CONDITIONS OF THE OFFER HAVE BEEN SATISFIED,
FULFILLED OR, WHERE PERMITTED, WAIVED, THE OFFER WILL BE EXTENDED FOR A
SUBSEQUENT OFFER PERIOD OF AT LEAST 14 CALENDAR DAYS. OGS SECURITYHOLDERS
WILL HAVE THE RIGHT TO WITHDRAW THEIR ACCEPTANCES OF THE OFFER FROM THE
DATE OF THIS ANNOUNCEMENT UNTIL THE SPECIFIED TIME ON THE LAST DAY OF THE
INITIAL OFFER PERIOD, BUT NOT DURING THE SUBSEQUENT OFFER PERIOD.

The Offer is conditional upon, among other things, valid acceptances being
received (and not, where permitted, being withdrawn) by 3:00 p.m. (London
time), 10:00 a.m. (New York City time) on 31 March 2003, or such later
time(s) and/or date(s) as Celltech may, subject to the City Code and in
accordance with the US Securities Exchange Act of 1934, as amended (the
"Exchange Act"), decide in respect of not less than 90 percent (or such
lesser percentage as Celltech may decide) of the OGS Shares (including
OGS Shares represented by OGS ADSs) to which the Offer relates, provided
that this condition will not be satisfied unless Celltech shall have
acquired, or agreed to acquire, pursuant to the Offer or otherwise, OGS
Shares (including OGS Shares represented by OGS ADSs) carrying in
aggregate more than 50 per cent of the voting rights normally exercisable
at a general meeting of OGS, including for this purpose (to the extent,
if any, required by the Panel) any voting rights attaching to any OGS
Shares (including OGS Shares represented by OGS ADSs) that are
unconditionally allotted or issued before the Offer becomes or is
declared unconditional as to acceptances pursuant to the exercise of
any outstanding subscription or conversion rights or otherwise.

Celltech reserves the right (but will not be obliged, other than as may
be required by the City Code or the Exchange Act) at any time or from time
to time to extend the Offer and, in such event, any decision to extend the
Offer will be publicly announced by 8:00 a.m. (London time) in the United
Kingdom and 8:00 a.m. (New York City time) in the United States on the
day (other than a Saturday or Sunday) following the day on which the
Offer was due to expire and which banks are generally open in London
for normal business. Except with the consent of the Panel, the Initial
Offer Period for acceptances and withdrawals may not extend beyond
1:00 p.m. (London time), 8:00 a.m. (New York City time), on 30 April 2003.
The Directors of Celltech accept responsibility for the information
contained in this announcement, and, to the best of their knowledge and
belief (having taken all reasonable care to ensure such is the case), the
information contained in this announcement is in accordance with the facts
and does not omit anything likely to affect the import of such information.
J.P. Morgan plc, which is regulated in the United Kingdom by the Financial
Services Authority, is acting for Celltech and for no one else in connection
with the Offer and will not be responsible to anyone other than Celltech for
providing the protections afforded to customers of JPMorgan or for providing
advice in relation to the Offer, the contents of the Offer Document or any
transaction or arrangement referred to therein.
The Panel wishes to draw the attention of member firms of NASDAQ to certain
UK dealing disclosure requirements during the offer period. The offer period
(in accordance with the City Code, which is published and administered by
the Panel) commences at the time when an announcement is made of a proposed
or possible offer, with or without terms. OGS has equity securities traded
on the London Stock Exchange and NASDAQ.
The above disclosure requirements are set out in more detail in Rule 8 of
the City Code. In particular, Rule 8 requires public disclosure of dealings
during the offer period by persons who own or control, or who would as a
result of any transaction own or control, one per cent. or more of any class
of relevant securities of the offeree company. Relevant securities include
OGS Shares, OGS ADSs and instruments convertible into OGS Shares or OGS
ADSs. This requirement will apply until the first closing date or, if
this is later, the date when the Offer becomes or is declared unconditional
or lapses. Disclosure should be made on an appropriate form by no later
than 12 noon (London time), 7 a.m. (New York City time) on the business
day following the date of the dealing transaction. These disclosures
should be published through a Regulatory Information Service.

The Panel requests that member firms advise those of their clients who
wish to deal in the relevant securities of OGS, whether in the United
States or in the United Kingdom, that they may be affected by these
requirements. If there is any doubt as to their application the Panel
should be consulted (telephone number: +44 (0) 20 7382 9026, fax
number: +44 (0) 20 7638 1554). This announcement has been approved by
J.P.Morgan plc for the purpose of section 21 of the Financial Services
and Markets Act 2000 only.
END